Lee, Yi-Hsuan
Huang, Chung-Yen
Hsieh, Yu-Han
Yang, Chia-Hung
Hung, Yu-Ling
Chen, Yung-An
Lin, Yu-Chieh
Lin, Ching-Hung
Lee, Jih-Hsiang
Wang, Ming-Yang
Kuo, Wen-Hung
Lin, Yen-Yin
Lu, Yen-Shen
Article History
Received: 18 May 2023
Accepted: 12 December 2023
First Online: 24 January 2024
Declarations
:
: All procedures were in accordance with the ethical standards established by the Declaration of Helsinki and the study protocol was approved by National Taiwan University Hospital (IRB reference number: 202004032RSB). Each participant provided written informed consent.
: Not applicable.
: This work was supported by JelloX Biotech Inc. through an industry-academia partnership. Hsieh YH, Yang CH, Hung YL, Chen YA, Lin YC, and Lin YY are employees of JelloX Biotech Inc. Yen-Shen Lu reports a relationship with Novartis Pharmaceuticals Corporation, F Hoffmann-La Roche Ltd, Eli Lilly and Company, Pfizer, AstraZeneca, Daiichy Sankyo, MSD that includes: consulting or advisory, funding grants, speaking and lecture fees, and travel reimbursement. All other authors declare no competing interest.